Division of Urology/Department of Surgery, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ.
Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ.
Urology. 2020 Jul;141:33-38. doi: 10.1016/j.urology.2020.03.049. Epub 2020 Apr 16.
To determine preference-based (utility) assessments of health-related quality of life (HRQoL) in kidney stone patients, and evaluate the association between these and disease specific, psychometric health status-based HRQoL scores (obtained via the Wisconsin Stone Quality of Life [WISQOL]).
One hundred four adults with urolithiasis, as well as 78 young healthy adults without history of urolithiasis (controls) were consecutively enrolled, meeting the predetermined recruitment goal. Each participant completed the SF-36 v2 (from which SF-6D utility is calculated) and EQ-5D questionnaires, while urolithiasis patients additionally completed the WISQOL. Relationship between health utility and WISQOL scores was evaluated using Pearson's test and multivariable linear regression analysis (MVA). Construct validity of the utilities for urolithiasis was assessed by comparing utilities for patients vs controls, and for symptomatic vs asymptomatic patients.
Mean (SD) WISQOL standard score, SF-6D, and EQ-5D utilities in stone patients respectively were 63 (29.1), 0.68 (0.16), and 0.83 (0.17). SF-6D and EQ-5D utilities significantly correlated with WISQOL standard score (Pearson's r = 0.87 and 0.58, respectively; each P <.0001). On MVA, WISQOL standard score was a significant predictor of SF-6D and EQ-5D utilities, explaining 72.1% and 33.9% of the respective variances in the utilities. Median SF-6D and EQ-5D utility were significantly lower in patients vs controls (each P ≤.0009), and in symptomatic vs asymptomatic patients (each P ≤ .0002).
SF-6D, more so than EQ-5D utilities in urolithiasis patients are strongly associated with disease-specific WISQOL scores, suggesting they are optimal for preference-based HRQoL assessment in this population. Construct validity of the utilities in stone disease was demonstrated.
确定肾结石患者健康相关生活质量（HRQoL）的偏好（效用）评估，并评估这些评估与特定疾病、基于心理测量健康状况的 HRQoL 评分（通过威斯康星结石生活质量[WISQOL]获得）之间的关系。
连续招募了 104 名患有尿路结石的成年人以及 78 名没有尿路结石病史的年轻健康成年人（对照组），达到了预定的招募目标。每位参与者都完成了 SF-36 v2（从中计算出 SF-6D 效用）和 EQ-5D 问卷，而尿路结石患者还额外完成了 WISQOL。使用 Pearson 检验和多变量线性回归分析（MVA）评估健康效用与 WISQOL 评分之间的关系。通过比较患者与对照组、症状性患者与无症状性患者的效用，评估效用在尿路结石中的结构效度。
结石患者的 WISQOL 标准评分、SF-6D 和 EQ-5D 效用的平均值（标准差）分别为 63（29.1）、0.68（0.16）和 0.83（0.17）。SF-6D 和 EQ-5D 效用与 WISQOL 标准评分显著相关（Pearson's r 分别为 0.87 和 0.58，均 P <.0001）。在 MVA 中，WISQOL 标准评分是 SF-6D 和 EQ-5D 效用的显著预测因子，分别解释了效用各自方差的 72.1%和 33.9%。与对照组相比（每项 P ≤.0009），患者的 SF-6D 和 EQ-5D 效用中位数明显更低，且症状性患者与无症状性患者相比（每项 P ≤.0002），亦是如此。
SF-6D 比尿路结石患者的 EQ-5D 效用更能与特定疾病的 WISQOL 评分密切相关，表明它们是该人群偏好基础 HRQoL 评估的最佳选择。在结石疾病中，效用的结构效度得到了证明。
